학술논문

A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling
Document Type
article
Author
Hackney, Jason AShivram, HaridhaHeiden, Jason VanderOverall, ChrisOrozco, LuzGao, XiaKim, EugeneWest, NathanQamra, AditiChang, DianaChakrabarti, ArindamChoy, David FCombes, Alexis JCourau, TristanFragiadakis, Gabriela KRao, Arjun ArkalRay, ArjaTsui, JessicaHu, KennethKuhn, Nicholas FKrummel, Matthew FErle, David JKangelaris, KirstenSarma, AartikLyon, ZoeCalfee, Carolyn SWoodruff, Prescott GGhale, RajaniMick, EranByrne, AshleyZha, Beth ShoshanaLangelier, CharlesHendrickson, Carolyn Mvan der Wijst, Monique GPHartoularos, George CGrant, TiannaBueno, RaymundLee, David SGreenland, John RSun, YangPerez, RichardOgorodnikov, AntonWard, AlyssaYe, Chun JimmieConsortium, UCSF COMETAbe-Jones, YumikoAdkisson, MichaelAnsel, K MarkAsthana, SaurabhBeagle, AlexanderBhide, SharvariCai, CathyCaldera, SaharaiCalvo, MariaCarrillo, Sidney AChak, SuzannaChristenson, StephanieCollins, ZacharyDarmanis, SpyrosDetweiler, AngelaDeVoe, CatherineEckalbar, WalterGiberson, JeremyGonzalez, AnaGordon, GracieSerpa, Paula HayakawaJauregui, AlejandraJones, ChayseKe, SerenaKushnoor, DivyaLea, TashaLee, DeannaLeligdowicz, AleksandraLiu, YaleMahboob, SalmanMaliskova, LenkaMatthay, MichaelMcCarthy, ElizabethMuñoz-Sandoval, PriscilaNeff, NormaNguyen, VietNigam, NishitaParada, RandyPhelps, MairaPierce, LoganPrasad, PriyaRashid, SadeedReeder, GabriellaRodriguez, NicklausSamad, BushraSchroeder, AndrewShaw, ColeShen, AlanSigman, AustinSinha, PratikSpitzer, MatthewSunshine, SaraTang, KevinAltamirano, Luz TorresTsitsiklis, Alexandra
Source
iScience. 26(10)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Immunology
Clinical Research
Clinical Trials and Supportive Activities
Lung
Acute Respiratory Distress Syndrome
Rare Diseases
Aetiology
2.1 Biological and endogenous factors
Good Health and Well Being
UCSF COMET Consortium
Clinical genetics
Immune response
Molecular medicine
Language
Abstract
Altered myeloid inflammation and lymphopenia are hallmarks of severe infections. We identified the upregulated EN-RAGE gene program in airway and blood myeloid cells from patients with acute lung injury from SARS-CoV-2 or other causes across 7 cohorts. This program was associated with greater clinical severity and predicted future mechanical ventilation and death. EN-RAGEhi myeloid cells express features consistent with suppressor cell functionality, including low HLA-DR and high PD-L1. Sustained EN-RAGE program expression in airway and blood myeloid cells correlated with clinical severity and increasing expression of T cell dysfunction markers. IL-6 upregulated many EN-RAGE program genes in monocytes in vitro. IL-6 signaling blockade by tocilizumab in a placebo-controlled clinical trial led to rapid normalization of EN-RAGE and T cell gene expression. This identifies IL-6 as a key driver of myeloid dysregulation associated with worse clinical outcomes in COVID-19 patients and provides insights into shared pathophysiological mechanisms in non-COVID-19 ARDS.